Loading...
•
Jun 30, 2022
Bicycle Q2 2022 Earnings Report
Reported second quarter 2022 financial results and provided corporate update.
Key Takeaways
Bicycle Therapeutics reported its second quarter financial results, highlighting clinical progress across its pipeline and the expansion of its collaboration with Genentech. The company's cash and cash equivalents totaled $372.8 million as of June 30, 2022, providing a financial runway into 2025.
Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528.
Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to Bicycle in Q3.
Cash and cash equivalents of $372.8 million as of June 30, 2022, excludes $9.8 million UK R&D tax credit received in July and Genentech payment.
Financial runway expected into 2025.
Forward Guidance
Bicycle Therapeutics anticipates continued advancement of its product candidates, including BT5528, BT8009 and BT7480, progression of its clinical trials, and expansion of its discovery efforts and early development pipeline.
Positive Outlook
- Advancement of product candidates.
- Progression of clinical trials.
- Expansion of discovery efforts.
- Early development pipeline growth.
- Strong balance sheet.
Challenges Ahead
- Risks to clinical trial site initiation.
- Patient enrollment and follow-up challenges.
- Uncertainties in clinical trials and development.
- Potential adverse effects from product candidates.
- Risk of inaccurate financial runway projections.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...